Healthcare Global Enterprises Limited (HCG), a leading provider of comprehensive cancer care in India, has announced the appointment of Manu Shankar Das as its new Chief Marketing Officer. The decision was approved by the company's Board of Directors on November 12, 2025, based on the recommendation of the Nomination and Remuneration Committee.

Appointment Details

Das is expected to join HCG on or before December 20, 2025, and will be part of the company's Senior Management Personnel. This strategic appointment comes as HCG continues to strengthen its leadership team and enhance its marketing capabilities.

Extensive Experience

Manu Shankar Das brings over 15 years of cross-industry marketing experience to his new role at HCG. His diverse background spans several sectors, including:

• Healthcare
• Interior Design
• Food & Hospitality
• Travel
• FMCG (Fast-Moving Consumer Goods)
• Information Technology

Areas of Expertise

Das's expertise covers a wide range of marketing disciplines, including:

• Performance marketing
• Brand strategy
• Product marketing
• Digital marketing
• Sales promotions

Professional Background

Prior to joining HCG, Das has held positions at several notable organizations:

• MediBuddy
• Rebbus
• Bonito Designs
• Flavors Unlimited

Additionally, Das has a background as a software engineer, with more than 12 years dedicated to marketing and branding roles.

Strategic Importance

The appointment of Manu Shankar Das as Chief Marketing Officer is expected to bolster HCG's marketing strategies and brand presence in the competitive healthcare sector. His diverse experience across multiple industries may bring fresh perspectives to HCG's marketing initiatives, potentially helping the company to expand its reach and strengthen its position as a leader in cancer care.

As HCG continues to grow its network of comprehensive cancer centers across India and Africa, Das's expertise in performance marketing and digital strategies could play a crucial role in enhancing the company's patient outreach and engagement efforts.

The healthcare industry, particularly in specialized fields like oncology, requires nuanced marketing approaches. Das's background in both healthcare and technology sectors positions him well to navigate the complexities of marketing advanced medical services while maintaining sensitivity to patient needs.

HCG's decision to bring in a marketing professional with such diverse experience signals the company's commitment to innovative marketing strategies in the evolving healthcare landscape. As the new Chief Marketing Officer, Manu Shankar Das will likely be tasked with elevating HCG's brand, driving patient engagement, and supporting the company's mission to make advanced cancer care accessible to a wider population.

Healthcare Global Enterprises Limited (HCG), a leading provider of specialized oncology services in India, has announced its unaudited financial results for the quarter and six months ended September 30, 2025, along with key corporate actions.

Financial Performance

For the quarter ended September 30, 2025, HCG reported:

The company's consolidated revenue from operations for Q2 FY2026 stood at ₹64,516 lakhs, marking a 16.8% increase from the corresponding quarter of the previous year. However, profit before tax decreased by 28.3% to ₹1,982 lakhs, while profit after tax remained relatively stable at ₹2,066 lakhs.

Employee Stock Option Allotment

The Board of Directors approved the issue and allotment of 7,537 equity shares of ₹10 each upon exercise of Employee Stock Options under the Employee Stock Option Scheme, 2021.

Board Meeting Details

The Board meeting, held on November 12, 2025, commenced at 10:30 a.m. and concluded at 5:30 p.m. During this meeting, the Board considered and approved the unaudited financial results for both standalone and consolidated operations.

Auditor's Review

BSR & Co. LLP, the statutory auditors, conducted a limited review of the financial results and issued an unmodified opinion. The review report notes that the acquisition of the oncology hospital business from HCG NCHRI Oncology LLP, completed in the previous financial year, has been accounted for in accordance with the requirements of Appendix C to Ind AS 103.

Strategic Investments

The Board has approved an investment of up to ₹700 lakhs (in equivalent USD) in equity shares of Cancer Care Kenya Limited, a step-down subsidiary of the company. This investment is subject to applicable regulatory approvals and is based on the fair value determined by an independent valuer.

Market Impact

While the company has shown strong revenue growth, the decrease in profit before tax may raise questions among investors about operational efficiency and cost management. The investment in the Kenyan subsidiary signals HCG's continued focus on international expansion in the oncology care sector.

HCG's commitment to employee ownership through the ESOP allotment may be viewed positively by the market as a strategy to align employee interests with company performance.